Identifying candidates with promising ADME and pharmacokinetics properties during the discovery phase of drug development lays the groundwork for future clinical trials and regulatory approval. However, translating a long-term study into a successful outcome requires reliable, qualified measurements at a clinical scale.
Q2 Solutions’ global bioanalytical services network brings substantial expertise in biomarker assays and cell-based bioanalytical assays that target multi-domain proteins, antibodies, oligonucleotides, antibody-drug conjugates, and peptides.
Specific strengths include:
Supporting data from high-volume, regulated clinical studies
Solutions for your large molecule bioanalysis and the successful outcome you seek
Your clinical trial may involve samples from multiple sites to be tested by multiple laboratories. The data that flows from those tests may travel to multiple end users as well. Proper planning of...
In this episode, the second of a three-part series, Alex Watt, Global Head for Biotech Integrated Laboratory Solutions and Alan Wookey, Global Head of Companion Diagnostics discuss how to manage...
Assessing the pharmacokinetics of biologics presents several analytical challenges, from the use of critical reagents and assay sensitivity requirements to regulatory and throughput considerations....